Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2020/09/027876
CTRI/2020/09/027876CompletedPhase 4

A Pilot Study to Evaluate Efficacy and Safety of Fixed Dose Combination of Pantoprazole 40 mg and Itopride 150 mg Capsules in Patients with Gastroesophageal Reflux Disease and Overlapping Symptoms of Dyspepsia

Abbott India limited0 sites50 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
50
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Pms

Eligibility Criteria

Inclusion Criteria

  • •1. Male and female patients above 18 years of age
  • •2. Patient who has read the informed consent form, has understood the relevant aspects of the clinical study, and grants his/her authorization to participate by signing the informed consent form before the inclusion in the clinical study and the performance of any procedure
  • •3. Patients who have at least a 3-month history of GERD symptoms along with overlapping symptoms of dyspepsia
  • •4. Presence of at least twice a week of heartburn and/or regurgitation and refractory to Pantoprazole 40 mg alone for at least 8 weeks
  • •5. Patients who have discontinued medications that affect esophageal motility or gastric acid secretion 1 week before enrolling into the study. These medications, include but not limiting to prokinetics, PPIs, H2 receptor antagonists, cholinergic and/or anti-cholinergic agents
  • •6. Patients willing to fill patient diaries and comply with the study procedure and requirements
  • •7. Female of childbearing potential must have a negative pregnancy test and be non-lactating at baseline visit
  • •8. Patient willing to use appropriate method of contraception as per investigatorâ??s discretion, throughout the study

Exclusion Criteria

  • •1. Patients with Barretts esophagus or esophageal stricture
  • •2. Patients with active or healing gastroduodenal ulcer (except scars)
  • •3. Patients with known cases of gastric, duodenal or esophageal surgery
  • •4. Patients with known cases of malignant disease of any kind
  • •5. Patients with heart failure or and clinically significant renal disease (serum creatinine more than 1.5 mg/dL)
  • •6. Patients with liver disease, low blood pressure, atrophic gastritis, Clostridium difficile related colitis, interstitial nephritis, osteoporosis, vitamin B12 deficiency, low amount of magnesium in blood
  • •7. Patients who have a problem of breathlessness 8. Patients with any other conditions or diseases that investigator considers it as inappropriate to enter the study as per prescribing information
  • •9. Smokers and patients with alcohol abuse
  • •10. Patients with known hypersensitivity to the active substance or any of the excipients
  • •11. Patients participated in any investigational drug trial within 4 weeks before screening
  • •12. Patients who require daily use of non-steroidal anti-inflammatory drugs (NSAIDS), oral steroids, or aspirin
  • •13. Patients taking any medications which might interfere with the action of the study drugs prior to the start of the study
  • •14. Patients who are unlikely to have visits at study sites or comply with study procedures
  • •15. Females who are pregnant/planning to become pregnant/not ready to use contraceptive measures or are lactating
  • •16. Patients who are unsuitable for any other reason to participate in the study in the opinion of the investigator

Investigators

Similar Trials

Recruiting
Phase 2
A observational study for safety and efficacy of Fulvestrant 500mg in postmenopausal patients with ER positive advanced or recurrent breast cancer after prior endocrine treatment. (SBCCSG-29)ocally advanced or metastatic breast cancer
JPRN-UMIN000009110Saitama Breast Cancer Clinical Study Group(SBCCSG)100
Active, not recruiting
Phase 1
A preliminary study to assess if low dose iron is safe and effective in patients with inflammatory bowel diseaseIron deficiency anaemia in inflammatory bowel diseaseMedDRA version: 20.0Level: LLTClassification code 10002062Term: Anaemia iron deficiencySystem Organ Class: 100000004851MedDRA version: 20.1Level: PTClassification code 10021972Term: Inflammatory bowel diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2018-002982-20-GBRoyal Liverpool University Hospital30
Active, not recruiting
Not Applicable
A pilot study to examine the efficacy and safety of escitalopram in doses up to 50 mg for the treatment of patients with Major Depressive Disorder (MDD). - Resistant Depression StudyMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive Disorder
EUCTR2008-003359-58-GBCPS Research60
Completed
Not Applicable
Validation study of the efficacy and safety of first precutting for Oral protrusion-Large, which is difficult to biliary duct cannulation.Cases requiring ERCP
JPRN-UMIN000042805Kitasato University School of Medicine38
Active, not recruiting
Not Applicable
A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemiaon Familial Chylomicronemia Syndrome (Non-FCS)MedDRA version: 14.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersNon Familial Chylomicronemia Syndrome (Non-FCS)
EUCTR2012-000872-40-CZovartis Pharma Services AG60